

Electronic Acknowledgement Receipt

EFS ID:	1679422
Application Number:	10726904
International Application Number:	
Confirmation Number:	4172
Title of Invention:	Use of the neurotoxic component of a botulinum toxin for treating various disorders and conditions and associated pain
First Named Inventor/Applicant Name:	Kei Roger Aoki
Correspondence Address:	STEPHEN DONOVAN ALLERGAN, INC. T2-7H 2525 Dupont Drive Irvine CA 92612 US 7142464249 -
Filer:	Stephen Donovan/Adriane Giberson
Filer Authorized By:	Stephen Donovan
Attorney Docket Number:	16952CON1CIP3 (BOT)
Receipt Date:	12-APR-2007
Filing Date:	02-DEC-2003
Time Stamp:	20:29:30
Application Type:	Utility

Payment information:

Submitted with Payment	yes
Payment was successfully received in RAM	\$1090
RAM confirmation Number	1263

Deposit Account	010885
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows: Charge any Additional Fees required under 37 C.F.R. Section 1.16 and 1.17	

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)	Multi Part /.zip	Pages (if appl.)
1	Miscellaneous Incoming Letter	16952-CON-CIP3-Transmittal-041207.pdf	384761	no	1

Warnings:

Information:

2	Extension of Time	16952-CON-CIP3-ExtOfTime-041207.pdf	392674	no	1
---	-------------------	-------------------------------------	--------	----	---

Warnings:

Information:

3	Request for Continued Examination (RCE)	16952-CON-CIP3-ReqRCE-041207.pdf	460736	no	1
---	---	----------------------------------	--------	----	---

Warnings:

This is not a USPTO supplied RCE SB30 form.

Information:

4	Information Disclosure Statement (IDS) Filed	16952-CON-CIP3-SuppIDS-041207.pdf	162089	no	5
---	--	-----------------------------------	--------	----	---

Warnings:

Information:

This is not an USPTO supplied IDS fillable form

5		16952CON1CIP3-Res2-041207.pdf	210113	yes	43
---	--	-------------------------------	--------	-----	----

Multipart Description/PDF files in .zip description

Document Description	Start	End
Amendment Submitted/Entered with Filing of CPA/RCE	1	3
Applicant Arguments/Remarks Made in an Amendment	4	36
Specification	37	37
Claims	38	43

Warnings:

Information:

6	Examination support document	ResponseExhibitsA-O.pdf	11473250	no	164
Warnings:					
Information:					
7	Oath or Declaration filed	Brin-Decl-Exhibits1-8.pdf	9893847	no	122
Warnings:					
Information:					
8	Foreign Reference	WO1994000481-A1.pdf	1206003	no	35
Warnings:					
Information:					
9	Foreign Reference	WO1994028923-A1.pdf	1017563	no	29
Warnings:					
Information:					
10	Foreign Reference	WO1995028171-A1.pdf	1442452	no	40
Warnings:					
Information:					
11	NPL Documents	Porton-Scrip.pdf	51882	no	1
Warnings:					
Information:					
12	NPL Documents	Athena-Makes.pdf	908253	no	2
Warnings:					
Information:					
13	NPL Documents	USFDA-OrphanList.pdf	1707027	no	65
Warnings:					
Information:					
14	NPL Documents	Adenis.pdf	318679	no	6
Warnings:					
Information:					

15	NPL Documents	Ambache-1951.pdf	837498	no	20
Warnings:					
Information:					
16	NPL Documents	Ambache-The.pdf	1959412	no	15
Warnings:					
Information:					
17	NPL Documents	Brin-Interventional.pdf	2244059	no	19
Warnings:					
Information:					
18	NPL Documents	Das.pdf	174407	no	6
Warnings:					
Information:					
19	NPL Documents	Dykstra.pdf	235612	no	5
Warnings:					
Information:					
20	NPL Documents	Elston-Paralytic.pdf	3846086	no	8
Warnings:					
Information:					
21	NPL Documents	Foster.pdf	307008	no	7
Warnings:					
Information:					
22	NPL Documents	Greene-1996-Movement Disorders.pdf	78658	no	4
Warnings:					
Information:					
23	NPL Documents	GreeneDevelopment.pdf	197639	no	6
Warnings:					
Information:					

24	NPL Documents	Haberman.pdf	93319	no	3
Warnings:					
Information:					
25	NPL Documents	Hambleton.pdf	343993	no	7
Warnings:					
Information:					
26	NPL Documents	Harper.pdf	137922	no	3
Warnings:					
Information:					
27	NPL Documents	Hatheway.pdf	929285	no	23
Warnings:					
Information:					
28	NPL Documents	Jenzer-Botulismus.pdf	3044295	no	25
Warnings:					
Information:					
29	NPL Documents	Khalafalla.pdf	171274	no	2
Warnings:					
Information:					
30	NPL Documents	Konstazer.pdf	331979	no	9
Warnings:					
Information:					
31	NPL Documents	Laccourreya.pdf	160315	no	3
Warnings:					
Information:					
32	NPL Documents	Ludlow.pdf	184319	no	3
Warnings:					
Information:					

33	NPL Documents	Memin.pdf	155312	no	5
Warnings:					
Information:					
34	NPL Documents	Montecucco.pdf	536189	no	9
Warnings:					
Information:					
35	NPL Documents	MoyerBotulinum.pdf	809936	no	15
Warnings:					
Information:					
36	NPL Documents	Moyer-Effects.pdf	959775	no	4
Warnings:					
Information:					
37	NPL Documents	Poungvarne-Two.pdf	1070606	no	7
Warnings:					
Information:					
38	NPL Documents	Price-A.pdf	965121	no	7
Warnings:					
Information:					
39	NPL Documents	Ransom.pdf	556941	no	9
Warnings:					
Information:					
40	NPL Documents	Ruusuvaara.pdf	537787	no	8
Warnings:					
Information:					
41	NPL Documents	Saga.pdf	264274	no	6
Warnings:					
Information:					

42	NPL Documents	Schurch.pdf	338209	no	8
Warnings:					
Information:					
43	NPL Documents	Scott-1988-MovementDisorders.pdf	110748	no	4
Warnings:					
Information:					
44	NPL Documents	ScottClinicalPreface.pdf	102211	no	4
Warnings:					
Information:					
45	NPL Documents	Tsui-Local.pdf	1669140	no	5
Warnings:					
Information:					
46	NPL Documents	Tsui-PilotStudy.pdf	241408	no	5
Warnings:					
Information:					
47	NPL Documents	Tang-Liu.pdf	663787	no	11
Warnings:					
Information:					
48	NPL Documents	Truong-BotB.pdf	2916227	no	4
Warnings:					
Information:					
49	NPL Documents	Wainwright.pdf	232169	no	5
Warnings:					
Information:					
50	NPL Documents	Wohlfarth.pdf	181659	no	3
Warnings:					
Information:					

51	Fee Worksheet (PTO-06)	fee-info.pdf	8503	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			57226411		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					